Christian Toouli retweeted
Missed the $ACW Clinical Trials Science Forum? No problem! A recording is available. Learn about the latest advancements in Alzheimer's trials & $ACWs commercialization strategies for Xanamem & watch a new video explaining its unique mechanism of action
youtu.be/QyfiLsSYQVg
Christian Toouli retweeted
$ACW CEO & CMO presenting at the Sachs Annual Neuroscience Forum in San Francisco (SFO) today. They are joined in SFO by the CFO & CCO, and the team will go on to participate in industry meetings associated with the Annual JP Morgan Healthcare Conference this week.
Christian Toouli retweeted
ACW CEO Steven Gourlay sat down with Sonia Madigan from Market Online to discuss the importance of the XanaCIDD trial results and the potential impact of Xanamem on depression treatment. He also touched on next steps.
themarketonline.com.au/actin… $ACW
Christian Toouli retweeted
ACW is excited to announce the results from the recent phase 2a XanaCIDD trial which show a clinically and statistically
significant improvement in depression.
See here for announcement. wcsecure.weblink.com.au/pdf/… $ACW
Christian Toouli retweeted
Attached is an article by Dr Tim Boreham published in the Biotech Daily discussing the history of Actinogen and its potential impact on patients suffering from cognitive impairment, depression and Alzheimer's disease. biotechdaily.com.au/wp/wp-co… #$ACW
Christian Toouli retweeted
Actinogen (ASX:ACW) publishes peer-reviewed paper summarising positive Xanamem phase 2a biomarker trial in 100th volume of the highly respected Journal of Alzheimer's Disease:m ow.ly/aicF50SpH9Y
Wonderful news!
I had brain #MRI scan last Thursday looking for recurrent #glioblastoma (&/or treatment complications). I found out yesterday that there is still no sign of recurrence. I couldn’t be happier!!!!!
Thank you to the fabulous team looking after me so well especially my wife Katie & wonderful family!
@SydneyLHD
@Sydney_Uni
Christian Toouli retweeted
Actinogen CMO, Dr Dana Hilt and guests explore the unique properties of Xanamem for the potential treatment of cognitive impairment in multiple diseases.
Forum details:
3pm AEST 23 May 2024
Event registration details contained in the announcement.
ow.ly/ACZ050RF4Qh
Christian Toouli retweeted
On Monday, I had further experimental treatment for my “brain cancer” #glioblastoma. This was delayed because there had been concerns about some of my blood test results. As a consequence, until recently, I hadn’t been exercising. But I am continuing to feel well. Thank you @ProfGLongMIA & other members of @MelanomaAus & the neuro-oncology team for facilitating my treatments.
I will be having another MRI brain scan next Thursday 9th May.
Hard to believe it’s nearly the one year anniversary since my initial seizure in #Poland & my #glioblastoma was discovered. Thank you to my wonderful wife Katie & my family, friends, colleagues & indeed everyone for all the incredible support I’ve been receiving - I am truly grateful!
@MelanomaAus
@SydneyLHD
@Sydney_Uni
Christian Toouli retweeted
Enrolment completed in XanaCIDD ph 2a cognition & depression trial
Full clinical trial enrolment now complete! Our XanaCIDD ph 2a trial of 167 patients with cognitive impairment in major depressive disorder is anticipated to read out in early Q3 this year
ow.ly/EHzh50RkNmp
Christian Toouli retweeted
Dose 8 (of 10) personalised anticancer vaccine administered last week as experimental treatment for my #glioblastoma. Sore arm for a couple of days but otherwise feeling good. Thanks @ProfGLongMIA, @mariag20057502 & @MelanomaAus team for organising & delivering! I hope everyone has enjoyed their weekend.
@MelanomaAus
@SydneyLHD
@Sydney_Uni
@parkrunAU
Christian Toouli retweeted
ACW’s CEO Dr Steve Gourlay is presenting today as one of the emerging leaders in the Small and Mid-Cap sector. Register for the conference here asx.arinex.one/
Christian Toouli retweeted
Fantastic news!!!!!!
Amazingly, my latest MRI brain scan shows no recurrence 10 months since my #glioblastoma presented with a seizure in #Poland. Median time to recurrence is 6 months.
I’m extremely hopeful that the novel #neoadjuvant combination #immunotherapy I’ve had & the scientific changes we demonstrated in my tumour post versus pre immunotherapy are being translated into clinical benefit! I’d be thrilled & very proud if this novel approach makes a difference for me & future #brain #cancer patients.
Thanks @ProfGLongMIA for devising & facilitating this superb approach & other members of multidisciplinary team including the @MelanomaAus team & other specialists @Dr_Brindha, Helen Wheeler, Michael Back & many others. Well done also to our @MelanomaAus translation research team including @HelenRizos! Special thanks for the ongoing support of my wife Katie, 3 kids Em, Matt & Luce, bro Mark, @subbie & many other family & friends!
@SydneyLHD
@Sydney_Uni
@MelanomaAus
@ausoftheyear
Christian Toouli retweeted
2024 is expected to be an exciting year as we accelerate development of #Deflexifol as an optimised therapeutic for millions of adults and children with #cancer.
#oncology #biotech
FivepHusion's CEO Christian Toouli discusses the end of 2023 and plans for the next 6 months 💊
@FivepHusion
#Investing #pharmaceutical #biotechnology #drugdevelopment
Christian Toouli retweeted
Thanks @tylahtully and @TheMarketBullAU for this editorial highlighting the promising signs of a #biotech recovery in 2024.
#investor #biotechnology #ASX #PharmaceuticalsBiotech
Despite challenges in 2023, the biotech sector is showing promise for 2024 with a surge in market momentum and encouraging IPOs, setting the stage for a robust year ahead! 💊🩺
@FivepHusion
#Investing #pharmaceutical #biotechnology #drugdevelopment
buff.ly/49foo8d
Christian Toouli retweeted
FivepHusion's CEO Christian Toouli discusses the end of 2023 and plans for the next 6 months 💊
@FivepHusion
#Investing #pharmaceutical #biotechnology #drugdevelopment
Great to chat with Rebecca Marsh and @TheMarketBullAU about our cancer drug #Deflexifol, 2023 partnering deals with @PfizerCentreone, @SyneosHealth, TreeHill Partners & @AllarityTx and future plans.
#biotech #Invest
FivepHusion's CEO Christian Toouli discusses its corporate strategies and focus for the next 6/12 months 💊👨⚕️
@FivepHusion
#DrugDevelopment #Pharmaceutical #BioTech
Christian Toouli retweeted
FivepHusion's CEO Christian Toouli discusses its corporate strategies and focus for the next 6/12 months 💊👨⚕️
@FivepHusion
#DrugDevelopment #Pharmaceutical #BioTech
Christian Toouli retweeted
FivepHusion have reached a significant milestone in its Deflexifol™ development with the first patient commencing treatment in its clinical trial 💉🩺
@FivepHusion
#Oncology #DrugDevelopment #Science #CancerResearch #Investing
buff.ly/459DXvh
Christian Toouli retweeted
A very exciting week, and important milestone, for the development of #Deflexifol™ as a promising new #therapy for the treatment of #paediatric ependymoma and other #brain tumours.
#oncology #drugdevelopment #science #CancerResearch #investors
anzchog.org/dartstudyopen/





















